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ABSTRACT
Introduction: Community pharmacy increasingly
features in global strategies to modernise the delivery
of primary healthcare. Medicine Use Reviews (MURs)
form part of the English Government’s medicines
management strategy to improve adherence and reduce
medicine waste. MURs provide space for patient–
pharmacist dialogue to discuss the well-known
problems patients experience with medicine taking.
However, ‘underserved’ communities (eg, black and
minority ethnic communities, people with mental
illness), who may benefit the most, may not receive
this support. This study aims to develop, implement
and evaluate an e-learning education intervention
which is coproduced between patients from
underserved communities and pharmacy teams to
improve MUR provision.
Methods and analysis: This mixed-methods
evaluative study will involve a 2-stage design. Stage 1
involves coproduction of an e-learning resource
through mixed patient–professional development (n=2)
and review (n=2) workshops, alongside informative
semistructured interviews with patients (n=10) and
pharmacy staff (n=10). Stage 2 involves the
implementation and evaluation of the intervention with
community pharmacy staff within all community
pharmacies within the Nottinghamshire geographical
area (n=237). Online questionnaires will be completed
at baseline and postintervention (3 months) to assess
changes in engagement with underserved communities
and changes in self-reported attitudes and behaviour.
To triangulate findings, 10 pharmacies will record at
baseline and postintervention, details of actual
numbers of MURs performed and the proportion that
are from underserved communities. Descriptive and
inferential statistics will be used to analyse the data.
The evaluation will also include a thematic analysis of
one-to-one interviews with pharmacy teams to
explore the impact on clinical practice (n=20).
Interviews with patients belonging to underserved
communities, and who received an MUR, will also be
conducted (n=20).
Ethics and dissemination: The study has received
ethical approval from the NHS Research Ethics
Committee (East Midlands–Derby) and governance
clearance through the NHS Health Research
Authority. Following the evaluation, the educational
intervention will be freely accessible online.
Strengths and limitations of this study
▪ The involvement of underserved communities in
the e-learning development process is central to
the coproduction model. This provides a plat-
form for their voices to be heard. It also incorpo-
rates the views of community pharmacy staff to
ensure the intervention is sensitive to the context
in which pharmacy teams deliver Medicine Use
Reviews (MURs).
▪ There is a risk of social desirability bias through
the implementation of self-reported question-
naires. We will seek to minimise this using self-
completion online questionnaires and not
through face-to-face completion.
▪ To triangulate findings, self-reported pharmacy
staff behaviour change will be compared with the
numbers of MURs performed with patients from
underserved communities at baseline and postin-
tervention. Pharmacy staff and patient interview
accounts will further inform the interpretation of
questionnaire findings and any impact on
practice.
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INTRODUCTION
Globally, community pharmacy increasingly features in
delivering new services to modernise primary health-
care, often in response to the growing demand on
general practitioners (GPs) and the shifting of care from
resource impoverished hospital settings to comparatively
cheaper care in the community.1 2 In England, one area
that has seen significant investment is pharmacy medi-
cine management services.3 This is due to increasing
recognition that patients experience widespread pro-
blems taking medicines and have concerns about
dependence, tolerance and side effects that affect medi-
cine adherence.4 How well people understand the
necessity to take their medicine(s) and how well sup-
ported (practically and psychologically) they are to do
so will also affect medicine use. One independent report
evaluating the scale, causes and costs of wasted medi-
cines estimates that in England alone, the annual cost of
NHS prescription medicines wastage is £300 million,
including £90 million worth of unused prescription
medicines that are retained in individuals’ homes and
£110 million returned to community pharmacies.5
To support medicine taking and to tackle problems of
non-adherence and medicine waste, community pharma-
cies are increasingly being commissioned to deliver new
services to support patient medicine taking.6 Since 2005,
the NHS Medicine Use Review (MUR) service has been
available from English community pharmacies. MURs
aim to support patients’ understanding and adherence
to therapy and to reduce avoidable waste.7 They involve
a patient–pharmacist face-to-face discussion, to establish
a picture of the patient’s medicine use and resolve medi-
cine problems or concerns that the patient may be
experiencing. Pharmacists must be accredited through
additional training before they offer the service.
Pharmacies claim £28 from the NHS for each MUR
undertaken and can undertake a maximum of 400
MURs in a financial year; meaning an annual total not
exceeding £11 200 per pharmacy is paid by the NHS.
Despite over 3 million MURs being conducted in
2015–2016,7 there have been questions over their value
to improve medicine use.8 9 The former Primary Care
Trusts have indicated they were not being targeted to
‘local needs and patient priorities’.10 Commercial and work
pressures have resulted in a ‘quantity driven’ approach
whereby pharmacists invite patients on simpler medicine
regimes that can be performed quickly, over those with
complex needs.11–13 Commissioners responded to these
concerns in 2011 and 2014, with reforms stipulating that
at least 70% of all MURs undertaken should be with
patients in higher risk groups (high-risk medicines,
respiratory and cardiovascular disease and people
recently discharged from hospital).
However, importantly, there is no obligation to target
patients from underserved or ‘seldom heard voice’ com-
munities (eg, people with disability, people who are
housebound, people from the black and minority ethnic
community, people with mental illness). Although
patients from these communities will have unique needs,
they are all less inclined to participate in health or screen-
ing services and have poorer health outcomes.14 There is
increasing evidence, suggesting that shared decision-
making interventions significantly improve outcomes for
disadvantaged patients and may be more beneficial to
these groups than higher literacy/socioeconomic status
patients.14 They may therefore benefit most from the
MUR service. With over 90% of all pharmacies in
England now providing MURs, there is a strong need for
an educational intervention to improve pharmacists’ atti-
tudes and behaviour towards underserved groups, so they
are not further marginalised from receiving MURs.
The coproduction philosophy, where health profes-
sionals and service users work in partnership to improve
the patients’ experience, is increasingly being used to
improve services to patients.15 16 The coproduction
concept is broad and can range from service coplanning
and cocommissioning, service codesign and codelivery,
through to service coassessment, comonitoring and coe-
valuation.17 Central to this idea is the contribution of
service users that allow services to be tailored while also
acknowledging the contribution from front-line health-
care staff.18 Such an educational intervention is uniquely
placed to address the clearly defined knowledge gaps
(eg, diversity awareness, unique needs of underserved
communities, cultural competence issues) present in the
case of MUR provision among pharmacists.
An e-learning intervention was identified as the most
appropriate and cost-efficient method to deliver the
training. E-learning tools have a track record in educat-
ing health professionals and are improving
health-related behaviours.19 20 They have also been iden-
tified by the NHS national learning strategy as a delivery
mechanism to ensure training is relevant and flexible
enough to take into account different learning styles21
as well as being an effective and flexible way to deliver
health professional training.22 In this paper, we present
the protocol for developing and evaluating the copro-
duced e-learning educational intervention.
Aims and objectives
This study aims to investigate whether an educational
intervention coproduced with patients and professionals
can change pharmacy staff attitudes and behaviour to
improve the provision of MURs to underserved commu-
nities. The primary objectives are to:
1. Coproduce, with patients from underserved commu-
nities and pharmacy teams, an e-learning resource
designed to change the attitudes and behaviour of
pharmacy staff to improve the provision of MURs to
underserved communities.
2. Evaluate the impact of the e-learning resource on
pharmacy staff’s reported behaviour scores on provid-
ing MURs to underserved communities.
3. Characterise pharmacy staff’s experience, perceived
impact on practice and to investigate barriers and facili-
tators to successful implementation of the e-learning.
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The secondary objectives are to:
1. Explore underserved patient experiences of medi-
cines and levels of support received from healthcare
professionals.
2. Investigate patients’ experiences of community phar-
macy service, their feelings of being offered and
undertaking an MUR and how this has affected their
knowledge of medicines and their use and percep-
tions of pharmacy services.
METHODS AND ANALYSIS
This study will be conducted in two stages (figure 1) at
multiple pharmacies. Multiple sources of data will be col-
lected to contextualise and converge lines of inquiry,
including prequestionnaire and postquestionnaire
surveys and qualitative interviews with patients and phar-
macy staff.
Description of e-learning educational intervention
The pharmacist e-learning educational intervention will
take the form of a series (2–4) of reusable learning
objects (RLOs). RLOs are small, pedagogically designed,
‘bite-sized’ chunks of e-learning that focus on a particu-
lar topic.22 The contents, including visual illustrations
and interactivities, will originate from mixed patient–
professional development workshops. These workshops
are designed to capture patient and pharmacy team
Figure 1 Study flow diagram.
Latif A, et al. BMJ Open 2016;6:e013500. doi:10.1136/bmjopen-2016-013500 3
Open Access
experiences and ideas on how staff can better engage
with patients from underserved communities.
Sample and recruitment
Stage 1: coproduce e-learning resource
Pharmacy teams and patient groups from underserved
communities will be recruited to workshops to
coproduce the e-learning resources to inform the inter-
vention. ‘Pharmacy teams’ will include participants from
the following groups (criteria outlined in box 1) who
will be sampled and recruited purposefully (n=15
participants).
▸ Community pharmacy staff (pharmacists, accredited
technicians, dispensers, medicine counter assistants).
▸ Superintendent pharmacists, community pharmacy
owners.
▸ Pharmacy representatives/professional leadership
bodies/educational bodies (ie, Nottingham Local
Pharmaceutical Committee (LPC), Royal Pharmaceutical
Society, Pharmacy Voice, Centre for Pharmacy
Postgraduate Education (CPPE)). EA is a CPPE tutor
who has experience running pharmacy education
workshops and will facilitate recruitment.
Patients from underserved communities will be recruited
via local organisations (n=15 participants) using the eligibil-
ity criteria detailed in box 2. These groups have been iden-
tified from the previous literature into the MUR service
and more recent work on the New Medicines Service
(NMS) evaluation study.23 Healthwatch Nottingham
(part of Healthwatch England), along with other organisa-
tions that represent underserved communities, will be
approached and will facilitate patient recruitment.
In addition, one-to-one interviews will be undertaken
with representatives from pharmacy teams (n=10) and
patients from underserved communities (n=10) to
further inform the e-learning intervention. The inclu-
sion/exclusion criteria will be as above (boxes 1 and 2).
Patient and public involvement
Two patient and public involvement (PPI) representa-
tives from undeserved communities, who are eligible
themselves for an MUR, will be recruited to form an
advisory panel for the study. PPI representatives will be
recruited via the East Midlands Academic Health
Science Network (AHSN) ‘Public Face’ newsletter. The
AHSN was established by NHS England in 2013 to
improve health and social care by bringing patients,
carers and communities together with health and social
care providers, industry and researchers.
The PPI advisory panel will meet regularly to advise
and challenge where necessary on the study design and
information included in the e-learning educational inter-
vention. Their involvement in the project will include
attending research meetings, workshops, providing feed-
back on the development of the RLOs and study findings.
They will bring their experience and expertise of the
world outside academia and their time living with a long-
term condition to ensure the patient voice is heard.
Stage 2: implementation and evaluation of the e-learning
educational intervention
The implementation and evaluation of the e-learning
intervention will be assessed through three work
streams.
Work stream 1: pre–postquestionnaire survey
All community pharmacies (n=237) in Nottinghamshire
will be approached to take part in the study. An
Box 2 Eligibility criteria for the selection of underserved
patients for reusable learning object development
workshop
Inclusion criteria
1. Patients (or organisational representative) identified as belong-
ing to (or representing) an underserved community. For the pur-
poses of this study, the term ‘underserved’ is used to describe
patients who are eligible to receive the Medicines Use Review
(MUR) service, but who, for whatever reason, not receive the
service. We define patients from ‘underserved’ communities as
including, but not limited to people with:
▸ People whose first language is not English
▸ People with physical, visual, hearing or learning impairments,
or any other disability
▸ Patients taking multiple medicines for more than one illness or
condition
▸ People who are housebound or their carers
▸ Black and minority ethnic communities
▸ People with mental illness
▸ People who are homeless or have no fixed address
▸ People from refugee, asylum and traveller communities
▸ People from Lesbian, Gay, Bisexual and Transgender
communities
▸ Men aged 16–25
2. Able to understand study information, willing and have capacity
to consent to take part in the workshops/interview
Exclusion criteria
1. Not belonging to (or representing) an underserved community
2. Unable to understand study information, unwilling or unable to
provide informed consent to the workshops/interview (transla-
tional services will be available should participants be unable to
read and converse in English)
Box 1 Eligibility criteria for the selection of pharmacy
teams
Inclusion criteria
1. Community pharmacy staff who have active involvement (on a
day-to-day basis) in identifying, inviting or undertaking
Medicine Use Reviews (MURs) within a community pharmacy
2. Willing to provide consent to take part in the workshop
activities/interview
Exclusion criteria
1. Pharmacy staff who are not actively involved with identifying,
inviting or undertaking MURs within a community pharmacy
2. Unwilling to provide consent to take part in the workshop activ-
ities/interview
4 Latif A, et al. BMJ Open 2016;6:e013500. doi:10.1136/bmjopen-2016-013500
Open Access
information sheet and invitation letter will be sent to
pharmacies which are currently providing the MUR
service to patients. Frequently, pharmacy support staff
are actively involved (on a day-to-day basis) in identify-
ing and inviting patients to the MUR service.
Pharmacists and their support staff will therefore be
invited to participate in this study. The study is not
powered to detect differences as there is no prior study
on which to base a power calculation. It is assumed that
90% of the pharmacies in Nottinghamshire (n=237) are
offering the MUR. With an estimated one pharmacist
and one support-staff expressing interest to be involved,
a response rate of 50% will give a minimum sample of
213 participants.
Work stream 2: qualitative appraisal of the educational
intervention: pharmacy staff interviews
Following completion of the postintervention question-
naire, a sample of pharmacists and support staff (n=20)
who have completed the online questionnaire will be
invited to take part in a semistructured interview to
further explore their experience of using the e-learning
educational resource and its impact on practice.
Work stream 3: qualitative appraisal of the MUR:
patient interviews
Following their MUR, a purposive sample of patients
from underserved communities that have had an MUR,
will be provided with information about the study by
the pharmacist. If the patient agrees to take part, a
one-to-one, face-to-face or telephone interview (n=20)
will be arranged. Interviews will explore their overall per-
ceptions of MURs, in particular, their experience of how
they were approached and engaged.
Study procedures
This study will involve two stages that will be undertaken
between August 2016 and March 2019 (figure 1).
Stage 1: workshops and interviews to coproduce e-learning
resource
The purpose of the workshops will be to help codevelop
an e-learning training package for pharmacists to
improve the provision and number of MURs to under-
served communities. Initial development workshops
(n=2) will focus on capturing themes through stories
and experiences, including design aspects such as pre-
ferred media, on ‘storyboards’ to elicit the contents of
the RLOs prior to production and enable an RLO speci-
fication to be written. The workshop will begin by pro-
viding participants with an outline of the day and
reminder that there are no right/wrong answers. An
‘appreciative’ method will be used throughout the work-
shop to promote inclusivity. Examples of existing RLOs
will be provided as well as an explanation of how they
are developed. Small groups will work to explore (on
flip-charts) what they think is important to include in a
pharmacy staff e-learning intervention. Anticipated RLO
topics may include: ‘identifying and learning about
underserved communities’, ‘effective targeting and invi-
tation strategies’ and ‘tailoring consultation skills to
meet the needs of underserved communities’.
Following initial concept ideas gathered from the
development workshops and interviews, an iterative
e-learning development process will be conducted with
two ‘review’ workshops with patients from underserved
communities and pharmacy teams. These workshops will
be identical to the development sessions, but will be
used to further develop and refine the e-learning specifi-
cation. This will enable the refinement of initial ideas
into a detailed specification (working title, learning
objectives, contents of topics covered) to be developed.
Workshops will be held at the University of Nottingham
and will be facilitated by AL (chief investigator (CI)),
HW, other members of the University’s HELM (Health
and E-Learning and Media) team and PPI panel repre-
sentatives will be present. A £200 inconvenience allow-
ance will be made available to all participants.
A review of the literature will ensure the contents are
factually correct. The specification will be peer reviewed
by experts in the field for clarity, factual content and
appropriateness of any animations. For example, the
peer review may identify errors in the content, and/or
suggest content changes to improve the e-learning.
These comments will be fed back to the author for revi-
sion of the specification and improvement.
Software development and further peer review of the
final RLOs will be undertaken before release.22 Errors
or problems with functionality that are identified will
require the e-learning to be reviewed by the developer.
Such errors are typically minor and do not require the
RLO to be further peer reviewed.
One-to-one semistructured interviews will be under-
taken by the CI with patients and pharmacists to further
inform the e-learning intervention. These interviews will
take place at a time and place convenient to the partici-
pant and, with consent, will be audio recorded.
Pharmacy staff will be invited to an interview to explore
existing practice and experience of providing MURs to
underserved groups and to identify knowledge gaps that
will help create the contents for the e-learning materials.
Patients from underserved communities who may be
unable or unwilling to attend a workshop (ie, people
who are housebound, traveller community) will be
invited. These interviews will explore medicine use,
support from other health professionals (eg, from the
practice nurse), perceptions of the pharmacy and views
on what would the patient like to see emphasised in an
e-learning intervention.
Piloting of RLOs and evaluation tools
The e-learning resource and online questionnaires will
be piloted on 10 undergraduate pharmacy students
from the University of Nottingham to test the functional-
ity of the RLOs and face validity of the data collection
instruments. This will be performed by asking students
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to work through the e-learning and checking ease of
use. Face validity of the questionnaire will also be
assessed.
Stage 2: implementation and evaluation
Following permission from the pharmacy owner/
manager, the pharmacist in charge of the pharmacy will
be contacted and will inform their team and provide
them with the study information. A poster will also be
sent to each pharmacy to be displayed in staff areas to
raise awareness. Assistance in recruiting pharmacies will
be sought from LPCs, other pharmacy bodies and the
NIHR Comprehensive Local Research Network (CLRN).
Implementation of e-learning and outcome measures
All pharmacy staff will be invited to complete an online,
baseline questionnaire which will be accessible over
3 weeks. Following baseline data collection (with a
reminder after 2 weeks), the online e-learning educa-
tional intervention will be made available to participants
for 30 days. A postintervention questionnaire will then
be sent at 3 months to those who completed the base-
line questionnaire (with one reminder). Consent to take
part will be implied through the completion of the
questionnaires.
The questionnaire will collect the following data: (1)
participant characteristics, that is, age, gender, educa-
tional achievement and details of any MUR training
received, years qualified as a registered pharmacist; (2)
pharmacy characteristics, for example, geographical
area, ownership type (eg, large multiples, supermarkets)
and economic deprivation (deprivation index will be
obtained through the UK Office of National Statistics
(ONS) data for each pharmacy using the postcode as
the lookup reference); (3) pharmacist and support-staff
attitudes will be assessed through attitudinal statements
developed from the ‘inequalities imagination’ frame-
work24 (this framework enables healthcare professionals
to more fully meet the needs of ‘underserved’ or ‘disad-
vantaged’ patients) and (4) pharmacist/support-staff
behaviour change assessed through a 12-item theory-
based instrument.25 This validated tool with robust
metric properties is used to assess the impact of continu-
ing professional development activities on health profes-
sionals’ clinical behavioural intention change.
Whereas self-reporting is a practical and efficient
method of collecting data, there are limitations such as
relying on respondents’ honesty and accuracy of report-
ing. In order to triangulate and support questionnaire
findings of self-reported behaviour with actual practice,
∼10 of the pharmacies taking part will be invited to
record the number of MURs performed and how many
were from underserved communities over a 2-week
period. The sample size for the number of pharmacies
included will be guided by the feasibility of data collec-
tion and resource constraints.
This will occur at baseline and at 3 months following
the e-learning.
Work stream 2: pharmacy staff interview
A purposeful sample of community pharmacy staff will
be invited to a one-to-one interview about their experi-
ence of the e-learning, its usability (barriers and facilita-
tors) of the RLOs and its effect on daily practice.
Written consent will be taken before the start of the
interview and permission sought for the interview to be
audio recorded. It will be explained to the potential par-
ticipant that entry into the study is entirely voluntary.
The interviews will last for ∼30 min and will be con-
ducted at the place of work or at any other convenient
location according to participant preferences.
Work stream 3: patient interviews
A purposeful sample of at least 10 community pharma-
cies will be recruited to help identify patients from
underserved groups. The pharmacist will sequentially
invite every eligible patient at the end of their MUR to
see if they are interested in taking part in the study. If
the patient expresses interest, the pharmacist will hand
them a study information sheet and seek consent
for their details to be passed onto the CI. The patient
will then be contacted by phone by the CI and the study
will be fully explained. They will then be given time to
decide whether to take part. If they agree, they will be
invited to interview. The purpose of the interview will be
to explore how the patient felt about being approached
and engaged for the MUR, whether the strategies that
were included in the e-learning were used by pharmacy
staff and what benefit the MUR had to improve medi-
cine understanding and use.
Analyses
Quantitative data analysis
Descriptive statistics will be used to describe participants’
demographic and baseline characteristics. Continuous
data will be presented using means and SDs if approxi-
mately normally distributed, and medians and IQR if
non-normally distributed. Categorical data will be
described using frequencies and percentages. To assess
the effect of the e-learning, baseline and postinterven-
tion data scores will be compared. Categorical variables
will be analysed using the χ2 test or Fisher’s exact test as
appropriate. Continuous data will be analysed using the
within-group t-test or Wilcoxon signed rank-test as
appropriate. Statistical significance will be assessed at the
5% (two-sided) level. All statistical analyses will be con-
ducted using IBM Statistical Package for Social Sciences
(SPSS) 22.
Qualitative data analysis
All interviews will be transcribed verbatim and the data
imported into qualitative analysis package NVivo; QSR
International Pty for the purpose of coding and thematic
analysis.26 Data analysis will start during the early stages
of data collection and proceed iteratively in order for
emergent findings to be incorporated into subsequent
data collection, including the revision of data collection
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tools, such as interview topic guides. A theoretical frame-
work around diversity and inequities in health will guide
qualitative data collection and analysis.24
Initial reading and rereading of the transcribed data
will be undertaken, with feedback and checking by
several members of the qualitative research team, to
identify common codes and categories. Actively search-
ing for disconfirming data will be undertaken as well as
regular detailed discussions among the qualitative
researchers and PPI advisory panel. Consideration will
then be given to how these issues group together in
broader themes related to the research objectives. The
principle of constant comparison will be used to test
and refine the empirical conceptual consistency of
codes and themes, which have been synthesised and
narrated.27
ETHICS AND DISSEMINATION
The study will be conducted in accordance with the
ethical principles that have their origin in the
Declaration of Helsinki, 1996; the principles of Good
Clinical Practice and the Department of Health
Research Governance Framework for Health and Social
Care, 2005. All participants will be informed that partici-
pation (in any stage of the study) will be voluntary and
that they may withdraw at any time.
Patient participation in workshops
Central to the development of the e-learning educational
intervention are the views of patients from underserved
communities. A coproduction methodology will be used
to enable patients and professionals to work in partner-
ship to codesign the pharmacy e-learning intervention.
By working alongside each other, a better understanding
of the barriers to approaching people from underserved
communities can be achieved. The collaborative
approach can lead to long-lasting change that genuinely
makes a difference to patients’ experience.28
However, patient participants from underserved com-
munities may be more vulnerable and harder to reach
or recruit than patients from the wider public who are
not from these communities. We will ensure patients are
fully informed about what is involved prior to the work-
shops. It is not anticipated that any participants will feel
marginalised during the workshops as we will be guided
by our PPI panel and use an ‘appreciative approach’
where all views will be valued. There will be sufficient
facilitators during the workshops to accommodate par-
ticipant needs. HW (Professor of e-Learning and Health
Informatics and coinvestigator) has extensive experience
in developing RLOs and will help facilitate the
workshops.
Patient participation in interviews
Face-to-face interviews will take place in the patient’s
home, pharmacy or any other location according to the
patient’s wishes. A telephone interview (or Skype/
FaceTime) option will also be available. Patients will
receive at least 24 hours or as long as is needed to
decide whether to take part in an interview. Interviews
are not expected to raise any distress or make the
patient upset as they will be centred on the patient’s
medicines, the levels of support they receive and how
services such as the MUR can help them.
Should the researcher become aware that the patient
requires urgent medical care, an intervention or is on the
wrong medicines, they will be referred to their pharma-
cist, their GP or other health professional as appropriate.
Dissemination
Following evaluation, the educational intervention will
be made freely available online and accessible to phar-
macy teams globally. The pharmacy workforce in the UK
is made up of ∼50 000 registered pharmacists with 70%
working within the community pharmacy sector.29 This
study therefore has the potential to have an immediate
beneficial impact for improving the delivery of MURs to
underserved patients. The intervention will be available
to the Centre for Pharmacy and Postgraduate Education
(CPPE) and Higher Education Institutes (HEIs) that are
responsible for pharmacist’s MUR competency assess-
ment and accreditation.
To support this study’s contribution to wider knowl-
edge, the research findings will be disseminated to
regional, national and international audiences through
conference and peer-reviewed publications targeted at
service users, health professionals, academics, service
commissioners and policymakers. We will also dissemin-
ate to pharmacy specific journals (eg, The Pharmaceutical
Journal and Chemist & Druggist) and social media (eg,
Twitter) to promote awareness.
CONCLUSION
This paper is an important step in the dissemination
process as it outlines the study’s background, aims and
details of methods that will be used. As well as providing
pharmacy staff with knowledge and practical skills to
engage patients from underserved communities, the
study will also contribute to addressing the significant
gap in the literature on how effective an intervention of
this nature will be in improving pharmacy practice. In
this respect, the study is novel and will provide informa-
tion on the feasibility of the educational intervention,
alongside the barriers and facilitators to implementa-
tion. Collectively, the findings from this study will act as
the first stage in developing the coproduction method-
ology within community pharmacy and how this can be
extended to address inequalities in other areas of phar-
macy practice.
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